AstraZeneca Gets Exclusive Japan Rights For Dapagliflozin From BMS, To Co-Promote With Ono
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca, Bristol-Myers Squibb, and Ono Pharmaceuticals announced a commercialization and sales collaboration for the new SGLT2 inhibitor dapagliflozin used for type 2 diabetes.